News

Filter

Current filters:

Asia-Pacific

126 to 135 of 96157 results

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA

08-09-2014

The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

New report debunks some common perceptions of R&D productivity

New report debunks some common perceptions of R&D productivity

08-09-2014

The 2014 edition of the Thomson Reuters CMR Pharmaceutical R&D Factbook, published today, contains some…

GlobalMarkets & MarketingPharmaceuticalRegulationResearch

Chugai launches ALK inhibitor Alecensa in Japan

Chugai launches ALK inhibitor Alecensa in Japan

07-09-2014

Japanese drugmaker Chugai Pharmaceutical said on Friday that it has launched the ALK inhibitor Alecensa…

AlecensaalectinibChugai PharmaceuticalJapanMarkets & MarketingOncologyPharmaceuticalRoche

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

07-09-2014

US specialty drugmaker Depomed says that Judge Kentaji Brown Jackson of the federal district court for…

DepomedGraliseLegalNeurologicalPharmaceuticalRare diseasesUSA

Eisai divests US Zonegran rights to Concordia

Eisai divests US Zonegran rights to Concordia

07-09-2014

Japanese drugmaker Eisai (TYO: 4523) says its US subsidiary has entered into an agreement to divest its…

BiotechnologyConcordia PharmaceuticalsEisaiMergers & AcquisitionsNeurologicalUSAZonegran

Novel vaccine cuts recurrence in HER2 positive breast cancer patients

Novel vaccine cuts recurrence in HER2 positive breast cancer patients

07-09-2014

A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy…

BiotechnologyGalena BioPharmaOncologyResearch

Soligenix acquires Ph III-ready oncology clinical program

Soligenix acquires Ph III-ready oncology clinical program

05-09-2014

US clinical-stage biopharma firm Soligenix has acquired a novel orphan drug candidate, known as SGX301…

BiotechnologyhypericinMergers & AcquisitionsOncologySGX301Soligenix

126 to 135 of 96157 results

Back to top